This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of -23.08% and 4.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 112.50% and 7.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.
ANSYS (ANSS) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
ANSYS' (ANSS) fourth-quarter performance is likely to have benefited from strength in the aerospace and defense, high-tech and automotive sectors.
WIX Set to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
WIX Q4 performance is likely to have benefited from an uptake of new products and improvement in the user base.
Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings
by Zacks Equity Research
Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.
Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.
Bristol Myers Squibb (BMY) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 13.64% and 0.28%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up
by Zacks Equity Research
Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to Vaxcyte to focus on technology development, inducing cost savings, to extend its cash runway to mid-2026. The stock rises 7%.
Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 19.05% and 0.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of -17.24% and 11.34%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Codexis (CDXS)? Wall Street Analysts Think 219%
by Zacks Equity Research
The consensus price target hints at a 219.4% upside potential for Codexis (CDXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 9.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 71.43% and 1.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -20.74% and 6.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis (CDXS) Surges 9.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Codexis (CDXS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 27.78% and 21.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Codexis (CDXS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Codexis (CDXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
After Plunging 39.6% in 4 Weeks, Here's Why the Trend Might Reverse for Codexis (CDXS)
by Zacks Equity Research
Codexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.